SCHEMBL283

SCHEMBL283

CC(C)(C)OC(=O)c1ccccc1-c1ccc(CBr)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.48
ACHE P22303 1/20 0.47
SLC6A4 P31645 3/20 0.46
BRS3 P32247 5/20 0.43
SCN1A P35498 3/20 0.43
SCN2A Q99250 3/20 0.43
SCN3A Q9NY46 3/20 0.43
SLC6A2 P23975 1/20 0.40
LTB4R2 Q9NPC1 3/20 0.40
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
BDKRB1 P46663 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9854183 0.89 ACHE (0.48) SLC6A3ACHESLC6A4BRS3SCN1A
SCHEMBL8875151 0.88 ACHE (0.48) SLC6A3ACHESLC6A4BRS3SCN1A
SCHEMBL489306 0.86 NR1H2 (0.48) SLC6A3ACHESLC6A4BRS3SCN1A
SCHEMBL4074654 0.85 ALDH1A1 (0.47) SLC6A3ACHESLC6A4BRS3LTB4R2
SCHEMBL18280658 0.85 CYP4F2 (0.45) SLC6A3ACHESLC6A4SCN1ASCN2A
SCHEMBL29390423 0.84 SLC6A3 (0.68) SLC6A3SLC6A4BRS3SLC6A2LTB4R2
SCHEMBL6900241 0.84 SLC6A3 (0.68) SLC6A3ACHESLC6A4BRS3SCN1A
SCHEMBL562 0.84 SLC6A3 (0.68) SLC6A3SLC6A4BRS3SLC6A2LTB4R2
SCHEMBL1069726 0.83 FOLH1 (0.47) ACHESCN1ASCN2ASCN3ALTB4R2
SCHEMBL9447390 0.83 ACHE (0.46) SLC6A3ACHESLC6A4BRS3SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106008356-B Preparation method of telmisartan 浙江华海药业股份有限公司 2023-02-28 CN claimed
CN-115108906-A Novel method for preparing 4 '-bromomethyl- [1,1' -biphenyl ] -2-tert-butyl formate 临海市华南化工有限公司 2022-09-27 CN claimed
CN-110156761-B Compound containing coumarin-biphenyl skeleton, preparation method and application thereof 郑州大学 2022-08-09 CN claimed
CN-113200934-B Compound containing benzomorpholone-biphenyl skeleton and preparation method and application thereof 郑州大学 2022-05-31 CN claimed
CN-113200934-A Compound containing benzomorpholone-biphenyl skeleton and preparation method and application thereof 郑州大学 2021-08-03 CN claimed
CN-110156761-A Containing cumarin-biphenyl backbone compound, preparation method and applications 郑州大学 2019-08-23 CN claimed
US-20060167301-A1 Process for producing an aralkyl compound, a dehalogenation method of an aralkyl halide compound and a method for recovering an aralkyl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2006-07-27 US claimed
EP-1683777-A1 A process for producing an aralkyl compound, a dehalogenation method of an aralkyl halide compound and a method for recovering an aralkyl compound Sumitomo Chemical Company, Limited (JP) 2006-07-26 EP claimed
EP-0389153-B1 Anti-stick layer for thermal printing MINNESOTA MINING & MFG (US) 1997-05-14 EP claimed
JP-3148266-A None JP disclosed
WO-2025011553-A1 AZOLE COMPOUNDS, SYNTHESIS THEREFOR AND PHARMACEUTICAL USE THEREOF 四川农业大学 2025-01-16 WO disclosed
CN-115215823-B FXR modulator, preparation method, pharmaceutical composition and application thereof 北京百思致道管理顾问中心(有限合伙) 2024-07-26 CN disclosed
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) 2024-07-18 US disclosed
EP-4324825-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Beijing Best Pathway Management Consulting Center (Limited Partnership) (CN) 2024-02-21 EP disclosed
EP-0400974-A2 Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 EP disclosed
EP-0400835-A1 Substituted benzimidazoles as angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 EP disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP disclosed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 WO disclosed
EP-0323841-A2 Substituted pyrrole, pyrazole and triazole angiotensin II antagonists E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-12 EP disclosed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF SLC10A1, NR1H4, FXR1 SLC6A3 1962/4885ACHE 4566/4885SLC6A4 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.